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Carriage and laboratory detection of multi-drug
resistant bacteria in low and middle-income
countries
P. Nordmann
INSERM U914, Kremlin-Bicêtre, France
Multidrug resistance is now emerging worldwide at an alarm-
ing rate among Gramnegatives, causing both community-acquired
and nosocomial infection. Themost important emerging resistance
traits are those reportedEnterobacteriaceae since they represent the
vastmajority of human infections. The emerging resistance traits in
Enterobacteriaceae are dominated by the clavulanic acid-inhibited
ß-lactamases (ESBLs) and the carbapenemases which hydrolyze
most if not all ß-lactams including the carbapenems. Detection of
infected patients rely on classical identiﬁcation of infecting agent
and susceptibility testing. Two biochemical tests, the ESBL NDP
and the Carba NP tests, have been recently developed for the early
detection of ESBL- or carbapenemase -associated resistance traits.
Those tests are rapid, sensitive, speciﬁc and cost-effective. Their
implementation can be done worldwide in any clinical microbiol-
ogy laboratory. Their extendedusagemay signiﬁcantly improve the
management and outcome of infected patients.
Detection of carriers is important mostly for patients hospital-
ized in ICUand important surgery. Taking in account theprevalence
rate of the ESBL and carbapenemase producers and the dynamic
of hospital-based outbreaks, detection of carriers is important for
detecting mostly K.pneumoniae, Enterobacter sp, . (and not E. coli)
which produce an ESBL and any enterobacterial species which pro-
duce a carbapenemase. This detection is based on a screening using
a selective plate containing a cephalosporin (ESBL producer) or a
carbapenem (carbaepenemase producer). A series of commercial-
ized and home-made (SUPERCARBA culture medium) are readily
available. Strains growing on thosemedia shall be screened rapidly
for ESBL producer b yusing the ESBL NDP test and for carbapen-
emase producer (Carba NP test). This strategy shall prevent the
development of outbreaks in hospitals among severely-ill patients
and preserve as much as possible the antibiotics of last resort.
http://dx.doi.org/10.1016/j.ijid.2014.03.554
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Antibiotic resistance and virulence
A. Brink
Milpark Hospital, Johannesburg, South Africa
Antimicrobial resistance, either by mutation or acquisition of
resistance determinants harboured by mobile genetic elements,
may confer a biological cost for the bacteria. This ﬁtness cost can
affect the growth rate in vitro or the survival in the host or in
the environment or the virulence capacity. However, bacteria can
evolve and adapt to reduce this cost, by compensatory mutations
or ﬁne regulation of resistance expression.Antibiotic resistance
may also be associated with increased virulence or transmission
and may play in role in global spread and dominance of certain
resistant bacteria, pending the plasmid type. In this regard, a suc-
cessful international sequence type, CTX-Mproducing E. coli ST131,
was shown to have a competitive advantage over other isolates
of E. coli, promoting its clonal expansion and dominance over less
virulent and/or more susceptible E. coli clones. In addition, Pitout
and colleagues demonstrated that NDM-1-producing E. coli ST131
had signiﬁcantly more virulence factors than NDM-1-producing
E. coli ST101. In contrast, amongst carbapenemase-producing
K.pneumoniae, the same authors found no signiﬁcant in vitro dif-
ferences in the presence of virulence factors between ST11, ST147,
ST258, and the other sequence types of carbapenemase-producing
K.pneumoniae globally, whilst Lavigne and colleagues showed in
their in vivo model, an increase of virulence of KPC-2 producing
strains belonging to ST-258. In fact, regarding the various CPE,
Nordmann and colleagues had also recently demonstrated discord-
ance amongst such pathogens, and a possible “ﬁtness cost” in vivo
due to the fact that not all carbapenemases are expressed to the
same extent of their in vitro expression. This has potential thera-
peutic implications for carbapenems and other antibiotic therapy
particularly for NDM and OXA-48-like infections but not appar-
ently for KPC infections according to their results. In summary,
although recent studies have demonstrated that antibiotic resis-
tance generally confers a reduction in ﬁtness e.g. MDR P.aeruginosa
and penicillin resistant N.meningitidis; the opposite may also be
true e.g. CA MRSA, agr dysfunction amongst bacteraemic MRSA
and ﬂuoroquinolone resistance of theNAP1/027C.difﬁcile epidemic
strains, and therefore appears to be distinct for every specie and
resistant genotype, pending compensatory evolution.
http://dx.doi.org/10.1016/j.ijid.2014.03.555
